MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1841-p
Abstract: Nonalcoholic steatohepatitis (NASH), characterized by hepatic steatosis, inflammation and fibrosis is an unmet medical need. MEDI0382, a balanced GLP-1/glucagon dual receptor agonist, is under development for the treatment of T2DM. Here we examined the effects… read more here.
Keywords: glp glucagon; self astrazeneca; self; medi0382 ... See more keywords